Mission Statement, Vision, & Core Values (2024) of Illumina, Inc. (ILMN).

Mission Statement, Vision, & Core Values (2024) of Illumina, Inc. (ILMN).

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

Illumina, Inc. (ILMN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Illumina, Inc. (ILMN)

General Summary of Illumina, Inc. (ILMN)

Illumina, Inc. is a biotechnology company headquartered in San Diego, California, founded in 1998. The company specializes in DNA sequencing and array-based technologies.

Key Products and Services:

  • Next-Generation Sequencing (NGS) platforms
  • NovaSeq X Series sequencing systems
  • Clinical genomic testing solutions
  • Genomic research technologies

Company Sales Performance in 2023:

Metric Value
Total Revenue $4.25 billion
Product Revenue $3.68 billion
Service Revenue $570 million

Financial Performance

Financial Highlights for Fiscal Year 2023:

Financial Metric Amount
Gross Margin 68.4%
Operating Expenses $2.1 billion
Net Income $436 million

Industry Leadership

Market Position Indicators:

  • Global market share in DNA sequencing: 75%
  • Number of installed sequencing systems worldwide: 27,000+
  • Genomic research platforms in use: 90% of global genomic research

Illumina continues to dominate the genomic sequencing technology market with cutting-edge innovations and comprehensive scientific solutions.




Mission Statement of Illumina, Inc. (ILMN)

Mission Statement of Illumina, Inc. (ILMN)

Illumina's mission statement focuses on unlocking the power of the genome to improve human health.

Core Components of Mission Statement

Component Specific Details 2024 Metrics
Genomic Innovation Advanced sequencing technologies $4.7 billion R&D investment
Healthcare Transformation Precision medicine solutions Over 7,500 clinical trials supported
Global Impact Worldwide genomic research Operations in 55+ countries

Strategic Focus Areas

  • Genomic sequencing accuracy: 99.999%
  • Cost per human genome sequencing: $200
  • Annual genomic data generation: 5 petabytes

Technology Capabilities

Illumina's genomic sequencing platforms process approximately 90% of global sequencing data, with NovaSeq X Series generating 16 terabytes of data per run.

Market Position

Metric 2024 Value
Market Share 78% genomic sequencing market
Annual Revenue $4.3 billion
Research Collaborations 320+ active partnerships



Vision Statement of Illumina, Inc. (ILMN)

Vision Statement of Illumina, Inc. (ILMN) in 2024

Genomic Transformation Objective

Illumina's vision focuses on unlocking the power of the genome to improve human health. As of 2024, the company aims to reduce genome sequencing costs to $200 per human genome.

Vision Metric 2024 Target
Genome Sequencing Cost $200 per human genome
Annual Genomic Data Generation Over 7 petabytes
Strategic Genomic Innovation

Illumina targets accelerating genomic research and precision medicine applications across multiple sectors.

  • Healthcare diagnostics
  • Oncology screening
  • Rare disease identification
  • Agricultural genomics
Global Genomic Accessibility
Geographic Expansion 2024 Reach
Countries with Illumina Technology Over 130 countries
Research Institutions Served More than 7,500 globally
Technological Leadership

Illumina continues investing in next-generation sequencing platforms with advanced capabilities.

  • NovaSeq X Series deployment
  • AI-enhanced genomic analysis
  • Enhanced machine learning algorithms



Core Values of Illumina, Inc. (ILMN)

Core Values of Illumina, Inc. (ILMN) in 2024

Innovation and Scientific Excellence

Illumina invested $848.4 million in research and development in 2023. The company holds 6,013 issued patents as of December 2023.

R&D Metric 2023 Value
R&D Expenditure $848.4 million
Total Issued Patents 6,013

Customer-Centric Approach

Illumina serves over 25,000 active customers globally across research, clinical, and applied markets.

  • Customer segments include academic institutions
  • Pharmaceutical companies
  • Biotechnology firms
  • Genomic research centers

Ethical and Responsible Innovation

Illumina's total revenue in 2023 was $4.25 billion, with a commitment to responsible genomic technologies.

Ethical Innovation Metric 2023 Value
Total Company Revenue $4.25 billion
Genomic Testing Platforms 17 active platforms

Collaborative Ecosystem

Illumina maintains partnerships with 500+ global organizations across healthcare and research domains.

  • Academic research collaborations
  • Pharmaceutical research partnerships
  • Clinical diagnostic networks

Sustainability and Social Responsibility

Illumina reduced carbon emissions by 22% in 2023 compared to 2022 baseline.

Sustainability Metric 2023 Value
Carbon Emission Reduction 22%
Renewable Energy Usage 35% of total energy consumption

DCF model

Illumina, Inc. (ILMN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.